<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Physiology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Physiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский физиологический журнал им. И.М. Сеченова</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-8139</issn><issn publication-format="electronic">2658-655X</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">651605</article-id><article-id pub-id-type="doi">10.31857/S0869813923010090</article-id><article-id pub-id-type="edn">IZJWJC</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>EXPERIMENTAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">14-3-3η Cytokine as a New Rheumatoid Arthritis Activity Assessing Biomarker</article-title><trans-title-group xml:lang="ru"><trans-title>Цитокин 14-3-3η как новый биомаркер в оценке активности ревматоидного артрита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korolkova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Королькова</surname><given-names>А. А.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shevaldina</surname><given-names>M. E.</given-names></name><name xml:lang="ru"><surname>Шевалдина</surname><given-names>М. Е.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rybakov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Рыбаков</surname><given-names>А. В.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ballyzek</surname><given-names>M. F.</given-names></name><name xml:lang="ru"><surname>Баллюзек</surname><given-names>М. Ф.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vavilova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Вавилова</surname><given-names>Т. В.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Maslyansky</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Маслянский</surname><given-names>А. Л.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vasiliev</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Васильев</surname><given-names>Д. С.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlova</surname><given-names>D. I.</given-names></name><name xml:lang="ru"><surname>Козлова</surname><given-names>Д. И.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khizha</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Хижа</surname><given-names>В. В.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yurieva</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Юрьева</surname><given-names>К. А.</given-names></name></name-alternatives><email>di.kozlova.official@gmail.com</email><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pitirim Sorokin Syktyvkar State University</institution></aff><aff><institution xml:lang="ru">Сыктывкарский государственный университет им. Питирима Сорокина</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Peter the Great St.Petersburg Polytechnic University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский политехнический университет Петра Великого</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт эволюционной физиологии и биохимии им. И.М. Сеченова РАН</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">St. Petersburg Clinical Hospital of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургская больница РАН</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр им. В.А. Алмазова МЗ России</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">St. Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-01-01" publication-format="electronic"><day>01</day><month>01</month><year>2023</year></pub-date><volume>109</volume><issue>1</issue><fpage>46</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2025-02-01"><day>01</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, А.А. Королькова, В.В. Хижа, Д.И. Козлова, Д.С. Васильев, А.Л. Маслянский, Т.В. Вавилова, М.Ф. Баллюзек, А.В. Рыбаков, М.Е. Шевалдина, К.А. Юрьева</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, А.А. Королькова, В.В. Хижа, Д.И. Козлова, Д.С. Васильев, А.Л. Маслянский, Т.В. Вавилова, М.Ф. Баллюзек, А.В. Рыбаков, М.Е. Шевалдина, К.А. Юрьева</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">А.А. Королькова, В.В. Хижа, Д.И. Козлова, Д.С. Васильев, А.Л. Маслянский, Т.В. Вавилова, М.Ф. Баллюзек, А.В. Рыбаков, М.Е. Шевалдина, К.А. Юрьева</copyright-holder><copyright-holder xml:lang="ru">А.А. Королькова, В.В. Хижа, Д.И. Козлова, Д.С. Васильев, А.Л. Маслянский, Т.В. Вавилова, М.Ф. Баллюзек, А.В. Рыбаков, М.Е. Шевалдина, К.А. Юрьева</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0869-8139/article/view/651605">https://journals.eco-vector.com/0869-8139/article/view/651605</self-uri><abstract xml:lang="en"><p id="idm45181322814608">Currently, rheumatoid arthritis routine diagnosis includes joint syndrome indicator determination such as tender and swollen joints count, as well as a number of laboratory indicators. The most interesting are the second ones, which include rheumatoid factor, antibodies to cyclic citrullinated peptide and a some acute-phase indicators, but they have low sensitivity and specificity, especially in the disease early stages, when it is still possible to normalize bring the age-norm indicators and get stable disease remission. Additionally, some of these medical tests are expensive enough and compulsory health insurance not-included. But, most importantly, there are no reliable rheumatologist modern practice disease activity assessing tools depending on the current-used treatment strategy. The article evaluates 14-3-3η protein usage possibility as a promising biomarker for rheumatoid arthritis immuno-inflammatory process activity in joints assessment. It was shown a higher studied indicator informative value (in terms of accuracy, sensitivity, specificity) in comparison with traditional acute-phase indicators, such as the erythrocyte sedimentation rate and C-reactive protein.</p></abstract><trans-abstract xml:lang="ru"><p id="idm45181322813952">В настоящее время рутинная оценка активности ревматоидного артрита заключается в определении показателей суставного синдрома, таких как число болезненных и припухших суставов, а также ряда лабораторных показателей. Наибольший интерес представляют последние, к числу которых относится ревматоидный фактор (РФ), антитела к циклическому цитруллинированному пептиду и ряд острофазовых показателей, однако они имеют низкую чувствительность и специфичность, особенно на ранних стадиях заболевания, когда еще есть возможность привести показатели к возрастной норме и достичь устойчивой ремиссии заболевания. Кроме того, некоторые из них весьма дороги и не покрываются обязательным медицинским страхованием. Несмотря на достижения современной науки до сих пор отсутствуют надежные инструменты оценки развития воспалительных процессов в суставах при ревматоидном артрите (РА) в зависимости от степени выраженности патологии и применяемой стратегии лечения. В статье анализирована возможность использования белка 14-3-3η как перспективного маркера оценки активности иммуновоспалительного процесса в суставах. Показана более высокая информативность (по характеристикам точности, чувствительности, специфичности) исследуемого показателя по сравнению с традиционными показателями острого воспаления, такими как скорость оседания эритроцитов и С-реактивный белок.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>activity</kwd><kwd>biomarker</kwd><kwd>14-3-3η protein</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>оценка активности воспаления</kwd><kwd>биомаркер</kwd><kwd>белок 14-3-3η</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Идея работы и планирование экспериментов (А.А.К., А.Л.М., Д.И.К., Д.С.В., М.Ф.Б., Т.В.В.), обследование пациентов исследуемых групп (А.А.К.), сбор биологического материала пациентов, включенных в исследование (А.А.К.), определение содержания 14-3-3η в плазме крови пациентов исследуемых групп (Д.И.К., В.В.Х., А.В.Р., М.Е.Ш., К.А.Ю.), обработка данных (А.А.К., А.Л.М., Д.И.К., Д.С.В., В.В.Х.), написание и редактирование манускрипта (А.А.К., А.Л.М., Д.И.К., В.В.Х.). Все авторы принимали участие в разработке концепции статьи и в написании рукописи. Окончательная версия рукописи была одобрена всеми авторами.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheumat Disease 69(4): 631–637. https://doi.org/10.1136/ard.2009.123919</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Karateev DE, Olunin YA (2008) About classification of rheumatoid arthritis. Rheumatol Sci Pract 5. https://doi.org/10.14412/1995-4484-2008-848</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheumat Disease 76: 960–977. https://doi.org/10.1136/annrheumdis-2016-210715</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fransen J, Stucki G, van Riel P (2003) Rheumatoid arthritis measures: Disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (radar), and rheumatoid arthritis disease activity index (Radai). Arthrit &amp; Rheumat 49(S5): S214–S224. https://doi.org/10.1002/art.11407</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthrit &amp; Rheumat 38(1): 44–48. https://doi.org/10.1002/art.1780380107</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheumat Disease 49(11): 916–920. https://doi.org/10.1136/ard.49.11.916</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheumat Disease 66(3): 407–409. https://doi.org/10.1136/ard.2006.054205</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Boers M, Tugwell P (1993) OMERACT conference questionnaire results. OMERACT Committee. J Rheumat 20(3): 552–554.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Boers M, Riel PLCM, Felson DT, Tugwell P (1995) Assessing the activity of rheumatoid arthritis. Baillière's Clin Rheumat 9: 305–317. https://doi.org/10.1016/s0950-3579(05)80192-x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bombardier CPACGW, Tugwell P, Sinclair A, Dok C, Anderson G, Buchanan W (1982) Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumat 9(5): 798–801.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hospital Jt Disease 66(3).</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Marhadour T, Jousse-Joulin S, Chalès G., Grange L, Hacquard C, Loeuille D, Sellam J, Albert JD, Bentin J, Chary Valckenaere I, D’agostino MA, Etchepare F, Gaudin P, Hudry C, Dougados M, Saraux A (2010) Reproducibility of Joint Swelling Assessments in Long-lasting Rheumatoid Arthritis: Influence on Disease Activity Score-28 Values (SEA-Repro Study Part I). J Rheumat 37(5): 932–937. https://doi.org/10.3899/jrheum.090879</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wells G, Li T, Maxwell L, Maclean R, Tugwell P (2008) Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheumat Disease 67(2): 260–265. https://doi.org/10.1136/ard.2007.069690</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Svedberg CA (1967) Normal erythrocyte sedimentation rate and age. Br Med J 2(5544): 85.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ramírez J, Narváez JA, Ruiz-Esquide V, Hernández-Gañán J, Cuervo A, Inciarte-Mundo J, Hernández MV, Sampayo-Cordero M, Pablos JL, Sanmartí R, Cañete JD (2017) Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Seminars Arthrit &amp; Rheumat 47(3): 303–309. https://doi.org/10.1016/j.semarthrit.2017.04.007</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kamel SR, Sadek HA, Mohamed FA, Osman HM (2018) Role of ultrasound disease activity score in assessing inflammatory disease activity in rheumatoid arthritis patients. Egypt Rheumat 40(1): 1–5. https://doi.org/10.1016/j.ejr.2017.04.002</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim K, Brixner DI (2018) The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Personal Med 15(4): 291–301. https://doi.org/10.2217/pme-2018-0001</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bensen WG, Jovaisas A, Thorne C, Baer P, Khraishi M, Dixit S, Choquette D, Starr M, Fortin I, Sholter D, Rampakakis E, Sampalis JS, Lehman AJ, Nantel F, Shawi M, Otawa S (2013) SAT0035 Variability in the Classification of Remission among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry. Ann Rheumat Disease 72(Suppl 3): A591–A592. https://doi.org/10.1136/annrheumdis-2013-eular.1761</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Syversen SW, Haavardsholm EA, Boyesen P, Goll GL, Okkenhaug C, Gaarder P I, van der Heijde D, Kvien TK (2010) Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheumat Disease 69(5): 845–850. https://doi.org/10.1136/ard.2009.122325</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, Eberl H, Klause U, Robinson WH (2011) Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthrit Res &amp; Therap 13(3): R102. https://doi.org/10.1186/ar3383</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler R (2010) Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120(6): 1848–1861. https://doi.org/10.1172/JCI39922</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Wener MH (2011) Multiplex, megaplex, index, and complex: the present and future of laboratory diagnostics in rheumatology. Arthrit Res &amp; Therapy 13(6): 134. https://doi.org/10.1186/ar3498</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Novikov A, Aleksandrova E, Gerasimov A, Cherkasova M, Karateev D, Luchikhina E, Nasonov E (2013) Multiparameter analysis of biomarkers in the laboratory diagnosis of early rheumatoid arthritis. Rheumat Sci and Practic 51(2): 111–116. https://doi.org/10.14412/1995-4484-2013-636</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Novikov A, Aleksandrova E, Nasonov E (2014) Elaboration and application of the diagnostic index based on multivariate analysis of biomarkers to determine the activity of rheumatoid arthritis. Rheumat Sci and Pract 52(1): 72–78. https://doi.org/10.14412/1995-4484-2014-72-78</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Maslaynski A, Lapin S, Mazing A, Bulgakova T, Lazareva N, Cheshuina M, Oleinick P, Ilivanova E, Totolyan A, Mazurov V (2012) Diagnostic value of serological markers of rheumatoid arthritis. Rheumat Sci and Pract 50(5): 20–24. https://doi.org/10.14412/1995-4484-2012-1175</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH (2007) Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheumat Disease 66(6): 712–719. https://doi.org/10.1136/ard.2006.054924</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>van der Pouw Kraan TCTM, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJM, Kraan MC, Fero M, Tak PP, Huizinga TWJ, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL (2003) Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthrit &amp; Rheumat 48(8): 2132–2145. https://doi.org/10.1002/art.11096</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kilborn S, Bukhari M (2018) AB0302 The role of the biomarker 14-3-3 eta in rheumatoid arthritis: a review. Rheumat Arthrit – Prognosis, Predictors and Outcome 1329.1–1329. https://doi.org/10.1136/annrheumdis-2018-eular.6614</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Lee DG, Woo JW, Kwok SK, Cho ML, Park SH (2013) MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med 45(4): e20–e20. https://doi.org/10.1038/emm.2013.39</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Bach M, Moon J, Moore R, Pan T, Nelson J, Lood C (2020) Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis. Arthrit &amp; Rheumat 72(1): 47–56. https://doi.org/10.1002/art.41062</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, Gui Y, Ghahary A, Kilani R, Marotta A (2014) 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthrit Res &amp; Therap 16(2): R99. https://doi.org/10.1186/ar4547</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Zhukov OS, Abolhosn RW, Popov JM, Naides SJ (2013) FRI0054 Elevated 14-3-3 eta in rheumatoid arthritis and arthritogenic viral infections. Ann Rheumat Disease 72(Suppl 3): A386.2–A386. https://doi.org/10.1136/annrheumdis-2013-eular.1181</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Kadavath S, Chittalae S, Nidal Shuaib O, Soon Goh K, Tosic M, Giles J, Efthimiou P (2014) SAT0211 14-3-3 ETA Protein: A Novel Biomarker for the Diagnosis of Rheumatoid Arthritis: Ann Rheumat Disease 73(Suppl 2): 666.1–666. https://doi.org/10.1136/annrheumdis-2014-eular.5776</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S, Mankin H, McShane DJ, Medsger T, Meenan R, Mikkelsen W, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F (1986) Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthrit &amp; Rheumat 29(8): 1039–1049. https://doi.org/10.1002/art.1780290816</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Metz CE (1978) Basic principles of ROC analysis. Sem Nuc Med 8: 283–298. https://doi.org/10.1016/s0001-2998(78)80014-2</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Maksymowych W, Landewé R, Tak P, Ritchlin C, Ostergaard M, Mease P, El-Gabalawy H, Garnero P, Gladman D, Fitzgerald O, Aletaha D, Bykerk V, Bathon J, Syversen S, Boers M, Geusens P, Inman R, Kraus V, Kvien T, Taylor W, Wells G, Van der Heijde D (2009) Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumat 36 (8): 1785–1791. https://doi.org/10.3899/jrheum.090346</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthrit &amp; Rheumat 63(3): 573–586. https://doi.org/10.1002/art.30129</mixed-citation></ref></ref-list></back></article>
